Duligotuzumab
Tools
Actions
General
Print/export
In other projects
Appearance
From Wikipedia, the free encyclopedia
Monoclonal antibody
Pharmaceutical compound
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | HER3 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG |
Duligotuzumab (INN) is a bispecific humanized IgG1 monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to EGFR and HER3.[1] It is in development by Roche. Clinical development for head and neck cancer and colorectal cancer have been discontinued, but phase I trials in combination with cobimetinib are evaluating safety for treatment of solid tumors.[2]
References
[edit]- ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
- ^ "Duligotuzumab". AdisInsight.
Angiopoietin |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
CNTF |
| ||||||||||
EGF (ErbB) |
| ||||||||||
FGF |
| ||||||||||
HGF (c-Met) |
| ||||||||||
IGF |
| ||||||||||
LNGF (p75NTR) |
| ||||||||||
PDGF |
| ||||||||||
RET (GFL) |
| ||||||||||
SCF (c-Kit) |
| ||||||||||
TGFβ |
| ||||||||||
Trk |
| ||||||||||
VEGF |
| ||||||||||
Others |
|
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
Hidden categories:
- Articles with short description
- Short description is different from Wikidata
- Chemicals that do not have a ChemSpider ID assigned
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a monoclonal antibody
- All stub articles